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the samples were collected after the viremic phase. Third, 
plaque-reduction neutralization testing was not performed, 
and because of the lack of convalescent serum, IgG sero-
conversion or titer increase were not evaluated; however, 
MAC ELISA is considered a valid technique for diagnos-
ing recently acquired infection with MAYV (10). Finally, 
the frequency of rash (Table), higher than in other case se-
ries (4), might be overestimated because of stringent selec-
tion criteria used for MAYV testing.
In conclusion, infection with MAYV occurs more 
frequently than expected in central Brazil. Mayaro fever 
should be considered in the differential diagnosis with 
DENV, CHIKV, and Zika virus infections in areas charac-
terized by arbovirus cocirculation.
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In March 2014, the World Health Organization declared an 
outbreak of Ebola virus disease in Guinea. In August 2014, 
a case caused by virus imported from Guinea occurred in 
Senegal, most likely resulting from nonsecure funerals and 
travel. Preparedness and surveillance in Senegal probably 
prevented secondary cases. 
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Table. Clinical characteristics of 15 patients positive for IgM 
against Mayaro virus, Goiânia, Goiás, Brazil, June 2014– 
June 2015 
Sign or symptom No. (%) patients 
Fever 15 (100) 
Arthralgia 14 (93) 
Joint edema 14 (93) 
Rash 14 (93) 
Headache 13 (87) 
Weakness 13 (87) 
Myalgia 12 (80) 
Eye pain 8 (53) 
Icterus 4 (27) 
Photophobia 3 (20) 
Severe itching 3 (20) 
Lymphadenopathy 2 (13) 
Vomiting 2 (13) 
 
1These authors contributed equally to this article.
2These authors contributed equally to this article. 
Ebola virus disease (EVD) is a hemorrhagic fever caused by Ebola virus (EBOV); the mortality rate is high (1,2). 
EBOV was discovered in 1976, simultaneously in Zaire 
(now the Democratic Republic of the Congo) and Sudan 
(3,4). Since then, small to large outbreaks have occurred 
sporadically in the Democratic Republic of the Congo, Su-
dan, Gabon, Uganda, Côte d’Ivoire, and Congo (5–7). 
In March 2014, the World Health Organization (WHO) 
reported an EVD outbreak caused by Zaire EBOV in Guin-
ea (8,9). The main feature of this outbreak was its exten-
sion into urban areas and neighboring countries (Liberia, 
Sierra Leone, Nigeria, Senegal, Mali). Ten countries on 3 
continents were affected; 28,646 confirmed, probable, and 
suspected cases and 11,323 deaths were recorded. 
In August 2014, Senegal was the fifth country in Africa 
to be affected by imported EBOV (10). We described this 
case, the patient’s itinerary and epidemiologic links with 
confirmed case-patients in Guinea, and the evolution of the 
disease and the virus.
The patient was a 21-year-old man from Forecariah, 
Guinea, who had traveled by land to Senegal during the 
night of August 13–14, 2014. The date of his illness on-
set was August 16, 2014; symptoms were fever, vomiting, 
diarrhea, yellow or black feces, anorexia, and asthenia. 
On August 18, he visited a suburban medical center in the 
suburbs of Dakar, where he received treatment for malaria: 
quinine, antipyretic and antimicrobial medications, and in-
travenous rehydration. Diarrhea and vomiting stopped on 
day 4 after illness onset, but fever and asthenia persisted. 
On August 26, the patient was admitted to Fann Hospital, 
Dakar, with slight dehydration, fever (39.2°C), and herpet-
ic lesions. Because no epidemiologic link with EVD was 
established, the patient was not isolated. 
On August 27, a total of 12 members of the patient’s 
family, all suspected of having EVD, were admitted to an 
Ebola treatment center in Conakry, Guinea; test results in-
dicated EBOV positivity for 6. Epidemiologic investigation 
indicated that a member of this family had traveled to Dakar 
and was hospitalized. The Epidemic Management Commit-
tee set up by WHO in Guinea established an epidemiologic 
link between the patient in Fann Hospital and the confirmed 
case-patients in Guinea and quickly informed the health au-
thorities in Senegal. The patient in Fann Hospital finally ac-
knowledged that he had attended his uncle’s nonsecure funer-
al in Guinea on August 10, before coming to Dakar (Figure). 
On August 28, the man was transferred to an isolation 
center, and blood samples were sent to the Institut Pas-
teur laboratory in Dakar, a WHO-approved collaborating 
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Figure. Timeline for case of Ebola virus disease imported into Senegal from Guinea, 2014. Flags indicate patient information; arrows 
indicate public health actions. BS, blood sample; RT-PCR, reverse transcription PCR.
Centre for EBOV diagnostics. Real-time reverse transcrip-
tion PCR (RT-PCR) was positive for Zaire EBOV; viral 
load was 2.04 × 104 genome copies/mL. ELISA of the same 
sample detected Zaire EBOV–specific IgM (titer 1:400) 
and IgG (titer 1:3,200). This case of EVD in Senegal was 
reported to WHO on August 29. The patient received sup-
portive care, and his clinical course progressed well; on 
August 31, he was apyrexic and his asthenia had decreased. 
In terms of virus evolution, a second blood sample tested 
on day 18 after illness onset showed diminution of viral 
load (4.96 × 103 genome copies/mL) and an IgG titer in-
crease to 1:6,400. A third blood sample collected on day 
20 showed a negative RT-PCR result, but a urine sample 
collected the same day showed a positive result with a viral 
load of 2.04 × 104 genome copies/mL. RT-PCRs of blood 
and urine collected on days 24 and 34 were negative, and 
serologic analyses showed a high IgG titer (1:12,800). 
The patient was declared cured on September 18, 2014. 
Epidemiologic investigations revealed a total of 74 contacts 
in Senegal, including 41 healthcare workers (from the sub-
urban medical center and Fann Hospital). Symptoms devel-
oped in 5 of these contacts, but their test results were negative 
for EBOV. No secondary case was detected after 42 days of 
monitoring, and the outbreak in Senegal was declared over 
on October 17, 2014, with only 1 confirmed case reported.
The case-patient’s low viral load, detected during the 
first RT-PCR 10 days after illness onset, probably explains 
the absence of secondary cases in Fann Hospital. However, 
the absence of secondary cases in the suburban medical 
center that the patient had visited on days 3–4 after illness 
onset and among the family members in Dakar is a rare 
feature of EVD. The preparedness and surveillance estab-
lished in Senegal after announcement of EVD in Guinea 
led to training of healthcare workers for proper use of 
protective equipment and security procedures with any 
patient, which probably prevented virus spread in the sub-
urban medical center. This case of EBOV importation from 
Guinea to Senegal confirms the problems encountered with 
Ebola outbreak management, including the roles of nonse-
cure funerals and travel in virus spread.
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